Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
Zhenro Properties $400 million high-yield notes offering
We advised Zhenro Properties on the Regulation S offering
Zhenro Properties $300 million high-yield notes offering
We advised the initial purchasers on the Regulation S senior notes offering
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…
JW (Cayman) Therapeutics HK$2.33 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…
Zai Lab HK$5.94 billion secondary listing and IPO on the HKEX
Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…